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a  b  s  t  r  a  c  t
A  new  self-assembled  formulation  of  methylprednisolone  succinate  (MPS)  based  on  a carboxylated
trifunctional  block  copolymer  of ethylene  oxide  and  propylene  oxide  (TBC-COOH)  was  developed.  TBC-
COOH  and  MPS  associated  spontaneously  at  increased  concentrations  in aqueous  solutions  to  form  almost
monodisperse  mixed  micelles  (TBC-COOH/MPS)  with  a hydrodynamic  diameter  of  19.6  nm,  zeta  potential
of −27.8  mV and  optimal  weight  ratio  ∼1:6.3.  Conditions  for  the effective  formation  of  TBC-COOH/MPS
were elucidated  by  comparing  copolymers  and  glucocorticoids  with  different  structure.  The  micellar
structure  of  TBC-COOH/MPS  persisted  upon  dilution,  temperature  ﬂuctuations  and  interaction  with  blood
serum components.  TBC-COOH  increased  antiradical  activity  of MPS  and  promoted  its  intrinsic  cytotoxi-
city  in  vitro  attributed  to enhanced  cellular  availability  of  the  mixed  micelles.  Intracellular  transportation
and  hydrolysis  of  MPS  were  analyzed  using  optimized  liquid  chromatography  tandem  mass  spectrometry
with  multiple  reaction  monitoring  which  showed  increased  level  of both  MPS  and  methylprednisolone
in  neuronal  cells  treated  with  the  formulated  glucocorticoid.  Our  results  identify  TBC-COOH/MPS  as  an
advanced  in  situ  prepared  nanoformulation  and  encourage  its  further  investigation  for  a  potential  local
glucocorticoid  therapy.
© 2018  Elsevier  B.V.  All  rights  reserved.
1. Introduction
Glucocorticoids are adrenal cortex derived, natural and
semisynthetic steroid hormones with pleiotropic biological activ-
ities in mammals [1]. They include cortisol (hydrocortisone), a
primary endogenous hormone, and a range of its synthetic deriva-
tives, such as dexamethasone, prednisolone, methylprednisolone
and their ethers. Glucocorticoids are one of the most frequently
used therapeutics with versatile effects on metabolic processes,
pronounced anti-inﬂammatory, immunomodulatory, anti-allergic
and anti-edema properties [1].
Besides routine use of glucocorticoids to treat widespread
diseases, including allergies, asthma, autoimmune and degener-
ative disorders [1], they are also considered as emergency drugs
administered in severe clinical cases, such as sepsis and acute neu-
ronal traumas [2,3]. Methylprednisolone infusion therapy has been
intensively studied in order to alleviate the consequences of acute
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spinal cord injuries which result from glutamate neurotoxicity and
inﬂammation [3,4]. The neuroprotective action of glucocorticoids
administered after hypoxia or traumatic injury was  established
[4–6]. This therapeutic effect is, however, observed within a rel-
atively narrow range of concentrations, and increased drug levels
could promote tissue degeneration [7].
The high therapeutic potential of glucocorticoids is accompa-
nied by their intrinsic side effects, including immunosuppression,
hypertension, osteoporosis, metabolic disturbances as well as
decreased sensitivity upon repetitive administration [1]. Develop-
ment of pharmaceutical approaches for reduction of these adverse
effects is of considerable biomedical interest. The common strategy
relies on the systemic use of glucocorticoids encapsulated into lipo-
somal or micellar nanocarriers designed for increasing solubility
and pharmacokinetic proﬁle of the drugs [6,8]. Localized delivery
of glucocorticoids to target tissues could provide substantial advan-
tages over systemic administration. The advantages are related to
improved safety and sustained therapeutic dose level. Localized
therapy should be based on an effective delivery system, incorpo-
rating medical devices, carriers and/or penetration enhancers. The
delivery systems are mainly designed to increase local bioavail-
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